Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “BONE REGENERATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 631 records · Page 35Linked to original sources

Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells.

Bone marrow contains a population of rare progenitor cells capable of differentiating into bone, cartilage, tendon, and other connective tissues. These cells, referred to as mesenchymal stem cells, can be purified and culture-expanded from animals and humans and have been shown to regenerate functional tissue when delivered to the site of musculoskeletal defects in experimental animals. To test the ability of purified human mesenchymal stem cells to heal a clinically significant bone defect, mesenchymal stem cells isolated from normal human bone marrow were culture-expanded, loaded onto a ceramic carrier, and implanted into critical-sized segmental defects in the femurs of adult athymic rats. For comparison, cell-free ceramics were implanted in the contralateral limb. The animals were euthanized at 4, 8, or 12 weeks, and healing bone defects were compared by high-resolution radiography, immunohistochemistry, quantitative histomorphometry, and biomechanical testing. In mesenchymal stem cell-loaded samples, radiographic and histologic evidence of new bone was apparent by 8 weeks and histomorphometry demonstrated increasing bone formation through 12 weeks. Biomechanical evaluation confirmed that femurs implanted with mesenchymal stem cell-loaded ceramics were significantly stronger than those that received cell-free ceramics. These studies demonstrate that human mesenchymal stem cells can regenerate bone in a clinically significant osseous defect and may therefore provide an alternative to autogenous bone grafts.

Animals↗

Clinical and microbiological observations of early polytetrafluoroethylene membrane exposure in guided bone regeneration. Case reports in primates.

Premature membrane exposure at one week is described in 3 Macaca mulatta monkeys as part of a sequence of experiments on guided bone regeneration. Clinical sequelae include redness, edema, and tissue slough. Bacteroides fragilis, Streptococcus pneumoniae, Prevotella intermedia, and Staphylococcus intermedius were detected at all prematurely exposed sites. Pseudomonas maltophilia, Strept, pneumoniae, and P. intermedia were the predominant organisms detected and consisted of more than 10% of the total anaerobic count.

Alveolar Bone Loss↗

Enhanced guided bone regeneration by controlled tetracycline release from poly(L-lactide) barrier membranes.

With the aim of providing effective periodontal therapeutic modality, drug-releasing membranes for guided tissue regeneration (GTR) were developed. As GTR membranes, biodegradable barrier membranes composed of porous poly(L-lactide) (PLLA) films cast on poly(glycolide) (PGA) meshes were fabricated using an in-air drying phase inversion technique. PLLA was dissolved in methylene chloride-ethylacetate mixtures, cast on knitted PGA mesh, and then air-dried. Tetracycline, which is used in periodontal therapy because of its antibacterial activity and tissue regenerating effects, including osteoblast chemotactic effect and anti-collagenolytic activity, was incorporated into the membranes by adding it to PLLA solutions. The guided bone regenerating potential of tetracycline-loaded membranes was evaluated using release kinetics both in vitro and in vivo, biodegradation tests, and cell attachment tests. Homogeneous pores were generated both at the surface and in a sublayer of the membranes. The release kinetics of tetracycline depended mainly upon the hydrophilicity of tetracycline and the porosity of the membrane. The release rate further could be controlled by loaded drug contents. The release of tetracycline was appropriate for maintaining anti-microbial activity and for its tissue-regenerating potential. The membranes retained a proper degradation property, maintaining their mechanical integrity for the barrier function for 4 weeks. Tetracycline-loaded membranes induced increased cell attachment levels compared with those of unloaded membranes. Tetracycline-loaded membranes markedly increased new bone formation in rat calvarial defects and induced bony reunion after 2 weeks of implantation. These results suggest that tetracycline-loaded PLLA membranes potentially enhance guided tissue regenerative efficacy.

Animals↗

Maintaining primary closure after guided bone regeneration procedures: introduction of a new flap design and preliminary results.

BACKGROUND: Various flap designs have been proposed by numerous authors for the maintenance of passive primary soft tissue closures following guided bone regeneration (GBR) procedures. A previous publication by the present author documented the maintenance of passive soft tissue primary closures 96.1% of the time at least 6 months after GBR therapy in all areas of the mouth. Although seemingly impressive, a 96.1% success rate means that there is premature membrane exposure 3.9% of the time. A new flap design is introduced for use in conjunction with previously described flap designs to lessen the incidence of premature membrane exposure. METHODS: A total of 173 sites treated with GBR therapy were examined up to 6 months postoperatively to assess the ability to maintain passive soft tissue primary closure. Any membrane exposure during this 6-month postoperative period was deemed a failure, even if the site was successfully treated with an implant placement and restoration. RESULTS: A total of 171 of 173 GBR-treated sites demonstrated the maintenance of a soft tissue passive primary closure 6 months postoperatively, yielding a success rate of 98.8%. CONCLUSION: The introduction of the proposed flap design for use in conjunction with previously described flap designs significantly reduced the incidence of premature membrane exposure after a variety of GBR procedures.

Adult↗

A novel injectable poly(epsilon-caprolactone)/calcium sulfate system for bone regeneration: synthesis and characterization.

A novel poly(epsilon-caprolactone)/calcium sulfate system was prepared and characterized in order to enhance calcium sulfate (gypsum) performance as bone graft substitute overcoming its brittleness and fast resorption rate. A poly(epsilon-caprolactone) (PCL) photo-crosslinkable derivative (PCLf) was synthesized by reaction of a low molecular weight PCL diol with methacryloyl chloride and confirmed by FT-IR and 1H NMR analyses. An injectable and easy mouldable mixture of PCLf and calcium sulfate hemi-hydrate (PCLf/CHS) was obtained. Thermal analyses and solvent extraction proved the occurrence of PCLf photo-crosslinking, even in the presence of CHS, in a time suitable for clinical applications. Swelling studies demonstrated that the encapsulation of the inorganic filler increases network hydrophilicity making it more permeable to water. Scanning electron microscopy, performed on crosslinked PCLf/CHS and on the same material after incubation in a PBS solution, showed the feasibility to obtain, in situ, gypsum entrapped into a degradable polymeric network. In vitro cytotoxicity tests, performed according to ISO 10993-5, proved that the developed system was not cytotoxic supporting its potential use in tissue engineering as a new, injectable, photocurable bone graft material. SEM micrograph of calcium sulfate di-hydrate (gypsum) entrapped in the PCL network.

3T3 Cells↗

Use of collagen membranes for guided bone regeneration: a review.

There has been an increase in the use of the resorbable membranes that do not require a second stage surgery for removal in guided bone regeneration. The purpose of this review is to discuss the immune response of the host to the collagen, the use of resorbable membranes derived from Type I collagen of bovine Achilles tendon around dental implants, and its potential significance in the future of dental implantology.

Absorbable Implants↗

Calcium sulfate-aided bone regeneration: a case report.

A technique is presented for treating periodontal osseous defects. Medical grade calcium sulfate hemihydrate is used as both a component of a composite graft with demineralized freeze-dried bone allograft (DFDBA) and a barrier over the graft to contain it and to exclude unwanted soft tissue. A case report is presented demonstrating clinical and radiographic success using the technique in the resolution of a severe osseous defect on a maxillary lateral incisor.

Alveolar Bone Loss↗

A stimulator of mouse stem cell proliferation produced by human regenerating bone marrow.

We examined CFU-S proliferation stimulator, which recruits stem cells in DNA synthesis, in conditioned media prepared from bone marrow cells of patients with regeneration hemopoiesis after chemotherapy induced hypoplasia. This activity was estimated by hydroxyurea sensitivity of CFU-S in mice, under conditions of incubation with human bone marrow conditioned medium (BMCM). We found that CFU-S proliferation stimulator was present to a considerable extent in human regenerating BMCM, but less so in normal BMCM and that the production fluctuated with change of hemopoietic states, in the same patient. This stimulator was heat-labile, trypsin-sensitive and mainly produced by adherent cells. This factor may possibly be involved in regulation of proliferation of stem cells in regenerating bone marrow in humans.

Animals↗

[Biosynthesis of pyrimidine nucleotides in normal and regenerating bone tissue].

RNA from bone tissue of healthy animals exhibited low specific radioactivity, when labelled orotic acid was used as precursor. These data suggest that the ability of sceletogenic cells to carry of formation of pyrimidine nucleotides was low. Labelled orotic acid and uridine were incorporated rapidly into regenerating bone tissue during the last days of the first week after the beginning of the regeneration process, gradually decreasing in course of maturation of the regenerated tissue.

Animals↗

Regenerating bone in clinical periodontics.

Bone autografts and allografts, various alloplastic materials, and guided tissue regeneration are used to reconstruct lost periodontal tissues. This paper focuses on controversies related to these therapeutic modalities as well as their role in periodontal regeneration.

Alveolar Bone Loss↗

Long-term results and survival rate of implants treated with guided bone regeneration: a 5-year case series prospective study.

One of the key factors for attaining osseointegration is the presence of an adequate osseous volume. In patients with inadequate osseous width or height, a bone augmentation using the guided bone regeneration (GBR) concept may be applied either with a simultaneous or a staged approach. The aim of this multicenter prospective case series study was to evaluate the efficacy and predictability of the GBR technique (simultaneous approach) in patients with peri-implant osseous defects, both dehiscences and fenestrations. Results 5 years post-treatment (survival rates and marginal bone level) were assessed. A total of 19 consecutive patients with 26 peri-implant osseous defects (20 dehiscences and six fenestrations) were treated during the period from September 1992 to June 1993 with a simultaneous GBR approach using non-resorbable membranes combined with autogenous bone grafts or decalcified freeze-dried bone allograft. The mean osseous augmentation was 94.8%. Marginal bone levels at re-entry and 5 years after surgery were calculated from standardized periapical radiographs. One implant was lost 3 months after loading. Thus, the cumulative survival rate was 96.1% after 5 years. The mean marginal bone level after 5 years was 2.03 mm (SD=+/-0.5), without a difference between mesial and distal sites. This study demonstrates that implants with peri-implant defects that are treated with GBR had similar survival rates and crestal bone levels compared with implants in native bone.

Adult↗